Autoimmune Encephalitis
Autoimmune encephalitis is a condition where the body's immune system mistakenly attacks the brain, leading to inflammation and a range of neurological symptoms.
Autoimmune Encephalitis: Satralizumab Study
We are testing the effectiveness and safety of satralizumab in patients with NMDAR or LGI1 mediated autoimmune encephalitis. The study aims to see if it improves disability and reduces symptoms compared to a placebo.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you diagnosed with NMDAR encephalitis or LGI1 encephalitis?
- Have you had symptoms of autoimmune encephalitis in the last 9 months?
- Do you have a history of cancer that has not returned in the last 5 years?
- Do you have any untreated teratoma or thymoma?
- Have you ever tested negative for anti-NMDAR antibodies in your cerebrospinal fluid within 9 months of your symptoms?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Johannes Kepler University Linz
University Clinic for Neurology
Linz, Austria
Medical University Of Vienna
Department of Neurology
Vienna, Austria
Fakultni Nemocnice Hradec Kralove
Neurologická klinika
Hradec Králové, Czechia
Sponsor: F. Hoffmann-La Roche AG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.